Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Predictions

buy
Teleflex Inc.

Start price
Target price
Perf. (%)
€308.00
20.11.20
-
20.11.21
8.44%
14.02.21

Revenue decline/stagnation expected
EBIT decline/stagnation expected
Low dividend yield expected
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€437.60
19.11.20
€426.00
19.11.21
1.19%
23.11.20

Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Standard Investments for future growth
buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€31.40
18.11.20
-
18.11.21
45.06%
19.11.21

EBIT growth >5% per year expected
Higher EBIT margin than peer group
Fair valuation
Low dividend yield expected
buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€31.31
16.11.20
-
5.61%
11.12.20

buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€51.30
14.11.20
-
14.11.21
-1.75%
23.11.20

Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€50.60
13.11.20
€52.00
1.38%
14.11.20

Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€50.00
09.11.20
€55.00
2.66%
10.11.20

Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
buy
Pfizer Inc.

Start price
Target price
Perf. (%)
€33.30
09.11.20
€37.95
-11.94%
17.12.20

Capable Management
Good culture
Innovative
Differentiated customer and product portfolio
buy
Humana Inc.

Start price
Target price
Perf. (%)
€364.00
03.11.20
-
04.11.21
-6.04%
14.01.21

Could be worthwhile Investment >10% per year
Differentiated customer and product portfolio
Higher risks for its business
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€49.75
31.10.20
-
04.11.21
0.53%
09.11.20

Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
buy
Agilent Technologies Inc.

Start price
Target price
Perf. (%)
€89.88
30.10.20
-
04.11.21
7.35%
03.01.21

Higher EBIT margin than peer group
Market Leader or Top 3
Known brand
Future proof or reliable business model
buy
Idexx Laboratories Inc.

Start price
Target price
Perf. (%)
€371.00
29.10.20
-
04.11.21
8.65%
30.12.20

EBIT growth >5% per year expected
Very low/no dividend yield expected
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€51.03
24.10.20
€58.00
04.11.21
-0.20%
11.11.20

Medium risks for its business
Risky Investment
buy
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€54.61
23.10.20
€55.00
31.10.20
-8.91%
31.10.20

Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
buy
Vertex Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€177.98
22.10.20
€170.00
04.11.21
-6.03%
05.11.21

Could be very worthwhile Investment >20% year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Rising EBIT margin expected
buy
Thermo Fisher Scientific Inc.

Start price
Target price
Perf. (%)
€406.60
22.10.20
€580.00
04.11.21
37.09%
05.11.21

Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
EBIT growth > 30% per year expected
Rising EBIT margin expected
buy
Intuitive Surgical Inc

Start price
Target price
Perf. (%)
€201.33
22.10.20
€216.67
04.11.21
4.35%
07.11.20

Known brand
Future proof or reliable business model
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
buy
Hologic Inc.

Start price
Target price
Perf. (%)
€56.50
20.10.20
€60.00
04.11.21
-11.63%
07.06.21

Could be worthwhile Investment >10% per year
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€51.42
20.10.20
€50.00
22.10.20
-1.26%
22.10.20

Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€514.00
03.10.20
-
04.11.21
-22.67%
11.03.21

Could be worthwhile Investment >10% per year
buy
Regeneron Pharmaceuticals Inc.

Start price
Target price
Perf. (%)
€514.00
03.10.20
€600.00
15.10.20
-1.81%
15.10.20

Known brand
Could be worthwhile Investment >10% per year
Future proof or reliable business model
Top 10 in its market
buy
Eli Lilly Corp.

Start price
Target price
Perf. (%)
€128.00
06.09.20
€125.00
04.11.21
-3.25%
06.11.20

Future proof or reliable business model
Higher risks for its business
Risky Investment
buy
PerkinElmer Inc.

Start price
Target price
Perf. (%)
€104.00
03.09.20
-
04.11.21
9.62%
05.11.20

Growths faster than the competition
Could be worthwhile Investment >10% per year
EBIT growth >5% per year expected
Gilead Sciences Inc

Start price
Target price
Perf. (%)
€55.32
26.08.20
€50.00
08.10.20
-2.68%
08.10.20

Known brand
Fair valuation
Leading role in innovation
Future proof or reliable business model
Pfizer Inc.

Start price
Target price
Perf. (%)
€30.93
25.08.20
€25.62
03.09.20
-2.45%
03.09.20

Capable Management
Good culture
Innovative
Differentiated customer and product portfolio